Our experience

Нour specialists have considerable experience in all common nosologies, and also have special

competence in conducting research of early phases.

Use the filter to select the categories of research and services you are interested in.

Services





Year





INNCodeАТСServicesYear
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bringing dossier into the EEU complience present
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Abacavir + Lamivudine + Zidovudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Bioequivalence CT 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2019-2020
Acetylcysteine R05CB Mucolytics Phase III CT 2019-2020
Ademetionin A16AA Amino Acids and Derivatives Marketing Authorization present
Agomelatine N06AX Other Antidepressants Bioequivalence CT 2019-2020
Albendazole P02CA Benzimidazole Derivatives Bioequivalence CT 2016-2018
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Phase III CT present
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization present
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2010-2012
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2016-2018
Amlodipine C08CA Dihydropyridine Derivatives Marketing Authorization 2019-2020
Amlodipine C08CA Dihydropyridine Derivatives Рharmacovigilance 2019-2020
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2010-2012
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Bioequivalence CT 2013-2015
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2016-2018
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors Marketing Authorization present
Ampicillin + Sulbactam J01CR Comb Of Penicillins, Incl. Beta-Lactamase Inhib. Marketing Authorization present
Amylmetacresol + Dichlorobenzyl alcohol R02AA Antiseptics Marketing Authorization present
Anagrelide L01XX Other Antineoplastic Agents Marketing Authorization present
Anastrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Aripiprazole N05AX Other Antipsychotics Bioequivalence CT present
Aripiprazole N05AX Other Antipsychotics Marketing Authorization present
Atazanavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Atazanavir J05AE HIV-proteinase inhibitors Marketing Authorization 2016-2018
Atracurium besilate M03AC Other Quaternary Ammonium Compounds Marketing Authorization 2013-2015
Atracurium besylate M03AC Other Quaternary Ammonium Compounds Рharmacovigilance 2019-2020
Aztreonam J01DF Monobactams Marketing Authorization present
Bendamustine L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Bleomycin L01DC Other Cytotoxic Antibiotics Marketing Authorization 2019-2020
Bortezomib L01XX Ингибиторы протеинкиназы Bringing dossier into the EEU complience present
Bosentan C02KX Antihypertensives for pulmonary arterial hypertension Bioequivalence CT 2016-2018
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2019-2020
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Bringing dossier into the EEU complience present
Caffeine + Paracetamol + Phenylephrine + Chlorphenamine N02B Other Analgesics and Antipyretics Marketing Authorization present
Capecitabine L01BC Pyrimidine Analogues Bioequivalence CT 2016-2018
Capreomycin J04AB Antibiotics Marketing Authorization 2010-2012
Carbamazepine N03AF Carboxamide Derivatives Рharmacovigilance 2019-2020
Carboplatin L01XA Platinum Compounds Marketing Authorization 2019-2020
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization present
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Phase III CT 2016-2018
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Cefoperazone J01DD Third-generation cephalosporins Marketing Authorization 2019-2020
Cefoperazone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization present
Cefoxitin J01DC Second-generation cephalosporins Marketing Authorization 2019-2020
Ceftriaxone J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Phase III CT 2013-2015
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization present
Celecoxib M01AH Coxibs Bioequivalence CT 2013-2015
Celecoxib M01AH Coxibs Bioequivalence CT 2016-2018
Celecoxib M01AH Coxibs Рharmacovigilance 2019-2020
Chlorambucil L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Chlormadinone + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2020
Chlorprothixen N05AF Thioxanthene Derivatives Bioequivalence CT 2019-2020
Cinacalcet H05BX Other anti-parathyroid agents Bioequivalence CT 2013-2015
Cinacalcet H05BX Other anti-parathyroid agents Marketing Authorization 2016-2018
Ciprofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Ciprofloxacin J01MA Fluoroquinolones PVG 2016-2018
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Cisplatin L01XA Platinum Compounds Рharmacovigilance 2019-2020
Citalopram N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization 2013-2015
Clarithromycin J01FA Macrolides Marketing Authorization 2010-2012
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2013-2015
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2016-2018
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Bioequivalence CT 2016-2018
Clotrimazole D01A Antifungals for topical use Marketing Authorization present
Cyclophosphamide L01AA Nitrogen Mustard Analogues Marketing Authorization 2019-2020
Cycloserine J04A Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2016-2018
Cycloserine + Pyridoxine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cyproterone G03HA Antiandrogens, Plain Preparations Marketing Authorization present
Cyproterone + Ethinylestradiol G03HB Antiandrogens and Estrogens Marketing Authorization 2013-2015
Cytisine N07BA Antismoking Agents Marketing Authorization present
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Marketing Authorization 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Darunavir J05AE HIV-proteinase inhibitors Bringing dossier into the EEU complience present
Dasatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Desogestrel + Ethinylestradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2020
Dexmedetomidine N05CM Other Hypnotics and Sedatives Marketing Authorization present
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids PVG 2016-2018
Dienogest + Ethinylestradiol G03FA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2013-2015
Dimetinden R06A Antihistamines for systemic use Marketing Authorization present
Diosmin + Hesperidin C05CA Bioflavonoids Marketing Authorization present
Docetaxel L01CD Taxanes Marketing Authorization 2013-2015
Docetaxel L01CD Taxanes Phase III CT 2016-2018
Docetaxel L01CD Taxanes Рharmacovigilance 2019-2020
Docetaxel L01CD Taxanes Marketing Authorization 2019-2020
Docetaxel L01CD Taxanes Marketing Authorization present
Domperidone A03FA Propulsives Marketing Authorization present
Donepezil N06DA Cholinesterase inhibitors Bioequivalence CT 2019-2020
Donepezil N06DA Cholinesterase inhibitors Marketing Authorization 2019-2020
Doripenem J01DH Carbapenems Marketing Authorization 2016-2018
Dorzolamide S01EC Carbonic Anhydrase Inhibitors Marketing Authorization 2016-2018
Doxorubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2016-2018
Drospirenone + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2020
Drospirenone + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2020
Drotaverine A03AD Papaverine and Derivatives Marketing Authorization 2010-2012
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Рharmacovigilance 2019-2020
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT present
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Enoxaparin B01AB Heparin Group Marketing Authorization 2019-2020
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Epirubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2010-2012
Epirubicin L01DB Anthracyclines and Related Substances Рharmacovigilance 2019-2020
Erlotinib L01XE Protein kinase inhibitors Marketing Authorization 2013-2015
Erlotinib L01XE Protein kinase inhibitors Bioequivalence CT 2013-2015
Esomeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Ethylmethylhydroxypyridine succinate N07XX Other Nervous System Drugs Phase III CT present
Etoposide L01CB Podophyllotoxin Derivatives Marketing Authorization 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT present
Famciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Famciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2013-2015
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Marketing Authorization 2016-2018
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Рharmacovigilance 2019-2020
Fingolimod L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Fluorouracil L01BC Pyrimidine Analogues Marketing Authorization 2016-2018
Flutamide L02BB Anti-Androgens Marketing Authorization 2016-2018
Fluvoxamine N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization present
Fosfomycin J01XX Other Antibacterials Marketing Authorization present
Gabapentin N03AX Other Antiepileptics Marketing Authorization 2013-2015
Ganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2016-2018
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2016-2018
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2010-2012
Gemcitabine L01BC Pyrimidine Analogues Рharmacovigilance 2019-2020
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization present
Gestodene + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2020
Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E M09AX Other Drugs For Disord. Of The Musc.-Skeletal Syst Marketing Authorization 2010-2012
Heparin B01AB Heparin Group Marketing Authorization 2013-2015
Hydrochlorothiazide + Losartan C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2010-2012
Hydroxycarbamide L01XX Other Antineoplastic Agents Marketing Authorization 2016-2018
Ibrutinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Ibuprofen M01AE Propionic Acid Derivatives Marketing Authorization present
Ibuprofen + Paracetamol M01AE Propionic Acid Derivatives Marketing Authorization present
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2013-2015
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Imatinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Imipenem + Cilastatin J01DH Carbapenems Marketing Authorization 2013-2015
Imipenem + Cilastatin J01DH Carbapenems Рharmacovigilance 2019-2020
Indapamide C03BA Sulfonamides, Plain Marketing Authorization 2010-2012
Iodixanol V08A X-Ray Contrast Media, Iodinated Marketing Authorization present
Iohexol V08AB Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media Marketing Authorization 2016-2018
Irbesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2013-2015
Irbesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2016-2018
Irinotecan L01XX Ингибиторы протеинкиназы Marketing Authorization present
Isoniazid J04AC Hydrazides Рharmacovigilance 2019-2020
Isoniazid + Pyrazinamide + Rifampicin J04AM Comb. Of Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Ivabradine C01EB Other Cardiac Preparations Marketing Authorization 2013-2015
Ivabradine C01EB Other Cardiac Preparations Bioequivalence CT 2013-2015
Josamycin J01FA Macrolides Marketing Authorization present
Ketoanalogues of aminoacids V06DD Amino Acids, Incl Combinations With Polypeptides Marketing Authorization 2019-2020
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2013-2015
Ketorolac trometamol M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Phase III CT 2016-2018
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Lamivudine + Zidovudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2013-2015
Lapatinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Latanoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Lenalidomide L04AX Other Immunosuppressive Agents Bioequivalence CT 2016-2018
Lenalidomide L04AX Other Immunosuppressive Agents Marketing Authorization 2016-2018
Letrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Levetiracetam N03AX Other Antiepileptics Marketing Authorization 2010-2012
Levocetirizine R06AE Piperazine Derivatives Bioequivalence CT 2013-2015
Levocetirizine R06AE Piperazine Derivatives Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2016-2018
Linezolid J01XX Other Antibacterials Marketing Authorization 2013-2015
Linezolid J01XX Other Antibacterials Bioequivalence CT 2013-2015
Linezolid J01XX Other Antibacterials Phase III CT 2013-2015
Linezolid J01XX Other Antibacterials Marketing Authorization 2016-2018
Loratadine R06AX Other Antihistamines for systemic use Рharmacovigilance 2019-2020
Losartan + Hydrochlorothiazide C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2013-2015
Lysocime + Pyridoxine R02AA Antiseptics Phase III CT present
Lysocime + Pyridoxine R02AA Antiseptics Marketing Authorization present
Meloxicam M01AC Oxicams Marketing Authorization 2016-2018
Menotropins G03GA Gonadotrophins Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2010-2012
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2019-2020
Mesalazine A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2013-2015
Metamizole sodium + Pitofenone + Fenpiverinium bromide N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Methotrexate L01BA Folic Acid Analogues Marketing Authorization 2016-2018
Metronidazole J01XD Imidazole Derivatives PVG 2016-2018
Metronidazole A01AB Antiinfectives For Local Oral Treatment Bringing dossier into the EEU complience present
Metronidazole + Chlorhexidine A01AB Antiinfectives For Local Oral Treatment Marketing Authorization present
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization 2016-2018
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization present
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Moxifloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Phase III CT 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Moxifloxacin J01MA Fluoroquinolones Рharmacovigilance 2019-2020
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents Marketing Authorization 2010-2012
Mycophenolic acid L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Naftifine D01A Antifungals for topical use Marketing Authorization present
Natamycin A07AA Antibiotics Marketing Authorization present
Natural phospholipids R07AA Lung Surfactants Marketing Authorization 2013-2015
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Nevirapine J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Nifuroxazide A07AX Other Intestinal Antiinfectives Marketing Authorization 2016-2018
Nilotinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Nilotinib L01XE Protein kinase inhibitors Marketing Authorization 2016-2018
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2013-2015
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2019-2020
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization present
Nitrofurantoin J01XE Nitrofuran derivatives Marketing Authorization 2016-2018
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Olmesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT present
Olmesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization present
Omeprazole A02BC Proton Pump Inhibitors Marketing Authorization present
Original drug B01AC Platelet Aggregation Inhibitors Excl. Phase III CT 2016-2018
Original drug J01DD Third-generation cephalosporins Phase III CT 2016-2018
Original drug J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Original drug B01AC Platelet Aggregation Inhibitors Excl. Marketing Authorization 2016-2018
Original drug G01BA Antibiotics and Corticosteroids Phase III CT 2019-2020
Original drug G01BA Antibiotics and Corticosteroids Marketing Authorization 2019-2020
Original drug J05AX Other Antivirals Marketing Authorization 2019-2020
Ornidazole J01XD Imidazole Derivatives Marketing Authorization 2010-2012
Ornidazole J01XD Imidazole Derivatives Рharmacovigilance 2019-2020
Ornidazole J01XD Imidazole Derivatives Marketing Authorization present
Ornidazole + Ciprofloxacin J01RA Combinations Of Antibacterials Marketing Authorization present
Oseltamivir J05AH Combinations Of Antibacterials Bioequivalence CT 2016-2018
Oseltamyvir J05AH Neuraminidase inhibitors Bringing dossier into the EEU complience 2019-2020
Oxaliplatin L01XA Platinum Compounds Bringing dossier into the EEU complience present
Pancreatin A09AA Enzyme Preparations Marketing Authorization present
Pantoprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Paracetamol N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Paracetamol N02B Other Analgesics and Antipyretics Phase III CT 2013-2015
Paracetamol N02B Other Analgesics and Antipyretics Рharmacovigilance 2019-2020
Paracetamol + Phenylephrine + Chlorphenamine maleate N02B Other Analgesics and Antipyretics Bioequivalence CT 2016-2018
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2020
Paracetamol + Phenylephrine + Pheniramine + Caffeine N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2020
Pazopanib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Peginterferon L03AB Interferons Phase III CT 2013-2015
Peginterferon alfa-2b L03AB Interferons Marketing Authorization 2016-2018
Phosphazide J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization present
Pimecrolimus D11AH Agents for atopic dermatitis, excluding corticosteroids Phase III CT 2013-2015
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Marketing Authorization 2010-2012
Posaconazole J02AC Triazole Derivatives Bioequivalence CT present
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2013-2015
Pregabalin N03AX Other Antiepileptics Marketing Authorization 2016-2018
Pregabalin N03AX Other Antiepileptics Рharmacovigilance 2019-2020
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2019-2020
Pyrazinamide J04AK Other Drugs For Treatment Of Tuberculosis Рharmacovigilance 2019-2020
Quetiapine N05AH Diazepines and oxazepines Bioequivalence CT 2016-2018
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2010-2012
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Rebamipide A02BX Other Drugs For Treatment Of Peptic Ulcer Marketing Authorization 2010-2012
Ritonavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Marketing Authorization 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2019-2020
Saquinavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Saquinavir J05AE HIV-proteinase inhibitors Marketing Authorization 2019-2020
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2013-2015
Sildenafil G04BE Drugs used in erectile dysfunction Marketing Authorization 2016-2018
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2016-2018
Sofosbuvir J05AP Antivirals for treatment of HCV infections Bioequivalence CT 2016-2018
Solifenacin G04BD Urinary Antispasmodics Bioequivalence CT 2016-2018
Sorafenib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Stavudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Sulodexide B01AB Heparin Group Phase III CT 2013-2015
Sulodexide B01AB Heparin Group PVG present
Sunitinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2010-2012
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2016-2018
Tamoxifen L02BA Anti-Estrogens Marketing Authorization 2016-2018
Teicoplanin J01XA Glycopeptide Antibacterials Phase III CT 2013-2015
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2016-2018
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT present
Telmisartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization present
Temozolomide L01AX Other Alkylating Agents Marketing Authorization 2010-2012
Temozolomide L01AX Other Alkylating Agents Bioequivalence CT 2016-2018
Temozolomide L01AX Other Alkylating Agents Рharmacovigilance 2019-2020
Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2016-2018
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Tigecycline J01AA Tetracyclines Marketing Authorization present
Timolol S01ED Beta Blocking Agents Marketing Authorization 2013-2015
Tobramycin J01GB Other Aminoglycosides Phase III CT 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Torasemide C03CA Sulfonamides, Plain Bioequivalence CT 2013-2015
Torasemide C03CA Sulfonamides, Plain Marketing Authorization 2016-2018
Tramadol N02AX Other Opioids Marketing Authorization 2016-2018
Tranexamic acid B02AA Amino Acids Marketing Authorization 2016-2018
Trastuzumab L01XC Monoclonal antibodies Marketing Authorization present
Travoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Urofollitropin G03GA Gonadotrophins Marketing Authorization 2013-2015
Ursodeoxycholic acid A05AA Bile Acid Preparations Bioequivalence CT present
Valaciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valganciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Valsartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2013-2015
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2016-2018
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors Bioequivalence CT present
Vildagliptin + Metformin A10BD Biguanides and Sulfonamides In Combination Bioequivalence CT present
Vinorelbine L01CA Vinca alkaloids and analogues Marketing Authorization present
Zidovudine + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015